Allovirincis A Clinical Stage Biotechnology Company Based In Walthammassachusettsfounded In 2013The Company Specializes In Developing Allogeneic T Cell Immunotherapies Aimed At Treating And Preventing Viral Infections In Immunocompromised Patientsallovir Focuses On Creating Off The Shelfmulti Virus Specific T Cell Therapies That Do Not Require Donor Matchingenhancing Accessibility For Patients The Company S Product Pipeline Includes Several Candidates At Various Clinical Stagesposoleucel Is In Late Stage Development For Multiple Viral Infectionswhile Alvr105 And Alvr106 Are In Phase 2 Trials Targeting Cytomegalovirus And Epstein Barr Virusrespectivelyallovir Collaborates With Leading Institutions Such As Baylor College Of Medicine And Memorial Sloan Kettering Cancer Center To Advance Its Therapiesthe Company Aims To Serve Immunocompromised Populationsincluding Stem Cell And Solid Organ Transplant Recipientsas Well As Oncology Patients Undergoing Intensive Chemotherapy
